Athira Pharma to Present Phase 2/3 LIFT-AD Trial Results at CTAD 2024; Shares Up 17%
Athira Pharma, Inc. (Nasdaq: ATHA), a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, announced that it will present the results of its Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 conference in Madrid. The presentation will take place on October 29, 2024.
The LIFT-AD trial did not meet the primary endpoint for statistical significance but showed favorable trends in cognition and function in certain subgroups of patients with moderate Alzheimer’s disease and APOE4 carriers. Biomarker data related to neurodegeneration and inflammation also showed positive trends consistent with fosgonimeton’s neuroprotective mechanism.
“We believe the totality of the data supports the potential of HGF modulation for the treatment of neurodegenerative diseases,” said Javier San Martin, M.D., Chief Medical Officer of Athira.
Athira’s shares are currently trading up 17% on the news.
The company continues to advance its pipeline, including the next-generation small molecule ATH-1105, currently in a Phase 1 trial as a potential treatment for ALS and Alzheimer’s disease, with further developments expected by year-end.